Table 1 Clinical characteristics of patients with melanoma and healthy controls. 40 patients with melanoma and 21 healthy individuals were included in the study. SMM superficial malignant melanoma, NMM nodular malignant melanoma, ALM acral lentiginous melanoma, NA not available.
From: Apelin promotes blood and lymph vessel formation and the growth of melanoma lung metastasis
Characteristics | Patients with melanoma (n = 40) | Healthy controls (n = 21) | ||
|---|---|---|---|---|
Numbers | % | Numbers | % | |
Gender | ||||
Male | 19 | 47.5 | 11 | 52 |
Female | 21 | 52.5 | 10 | 48 |
Age (years) | ||||
< 60 | 13 | 32.5 | 18 | 86 |
≥ 60 | 26 | 65 | 3 | 14 |
NA | 1 | 2.5 | 0 | 0 |
Co-morbidities | ||||
Arterial hypertension | 14 | 35 | 0 | 0 |
Cardiovascular diseases | 13 | 32.5 | 0 | 0 |
Diabetes | 5 | 12.5 | 0 | 0 |
Inflammatory diseases | 3 | 7.5 | 0 | 0 |
Asthma | 1 | 2.5 | 0 | 0 |
Renal disease | 1 | 2.5 | 0 | 0 |
None | 9 | 22.5 | 21 | 100 |
Breslow depth (mm) | ||||
< 0.75 mm | 2 | 5 | ||
0.76–3.99 mm | 25 | 62.5 | ||
> 4 mm | 10 | 25 | ||
NA | 3 | 7.5 | ||
Histological subtype | ||||
SMM | 14 | 35 | ||
NMM | 8 | 20 | ||
ALM | 2 | 5 | ||
NA | 16 | 40 | ||
Treatment | ||||
Immunotherapy | 7 | 17.5 | ||
Radiotherapy | 5 | 12.5 | ||
Immuno + Radiotherapy | 5 | 12.5 | ||
BRAF + MEK1.2 inhibitors | 3 | 7.5 | ||
Other | 5 | 12.5 | ||
None | 13 | 32.5 | ||
NA | 2 | 5 | ||
